Sense and nonsense in sensors

Continuous subcutaneous glucose monitoring (CGM) is a developing technology in the treatment of diabetes mellitus. The first randomised controlled trials on its efficacy have been performed. In several studies, CGM lowered HbA(1c) in adult patients with suboptimally controlled type 1 diabetes mellit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermanides, J., DeVries, J. H.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830625/
https://www.ncbi.nlm.nih.gov/pubmed/20225392
http://dx.doi.org/10.1007/s00125-009-1649-4
_version_ 1782178174523670528
author Hermanides, J.
DeVries, J. H.
author_facet Hermanides, J.
DeVries, J. H.
author_sort Hermanides, J.
collection PubMed
description Continuous subcutaneous glucose monitoring (CGM) is a developing technology in the treatment of diabetes mellitus. The first randomised controlled trials on its efficacy have been performed. In several studies, CGM lowered HbA(1c) in adult patients with suboptimally controlled type 1 diabetes mellitus, when selecting compliant patients who tolerate the device. However, as a preventive tool for hypoglycaemia, CGM has not fulfilled the great expectations. Increasing reimbursement of CGM is expected in the near future, awaiting studies on cost-effectiveness.
format Text
id pubmed-2830625
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-28306252010-03-15 Sense and nonsense in sensors Hermanides, J. DeVries, J. H. Diabetologia Commentary Continuous subcutaneous glucose monitoring (CGM) is a developing technology in the treatment of diabetes mellitus. The first randomised controlled trials on its efficacy have been performed. In several studies, CGM lowered HbA(1c) in adult patients with suboptimally controlled type 1 diabetes mellitus, when selecting compliant patients who tolerate the device. However, as a preventive tool for hypoglycaemia, CGM has not fulfilled the great expectations. Increasing reimbursement of CGM is expected in the near future, awaiting studies on cost-effectiveness. Springer-Verlag 2010-01-10 2010 /pmc/articles/PMC2830625/ /pubmed/20225392 http://dx.doi.org/10.1007/s00125-009-1649-4 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Commentary
Hermanides, J.
DeVries, J. H.
Sense and nonsense in sensors
title Sense and nonsense in sensors
title_full Sense and nonsense in sensors
title_fullStr Sense and nonsense in sensors
title_full_unstemmed Sense and nonsense in sensors
title_short Sense and nonsense in sensors
title_sort sense and nonsense in sensors
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830625/
https://www.ncbi.nlm.nih.gov/pubmed/20225392
http://dx.doi.org/10.1007/s00125-009-1649-4
work_keys_str_mv AT hermanidesj senseandnonsenseinsensors
AT devriesjh senseandnonsenseinsensors

Ejemplares similares